title: Analysis of granulysin-mediated cytotoxicity in peripheral blood of patients with psoriatic arthritis.
abstract: The objective of the present study was to investigate possible changes in granulysin (GNLY)-mediated cytotoxicity of peripheral blood lymphocytes in psoriatic arthritis (PsA) patients with respect to different phases of the disease. We prospectively enrolled 25 PsA patients in the active phase, 26 PsA patients in remission and 24 healthy controls. The simultaneous detection of intracellular GNLY and cell surface antigens (CD3 and CD56) was performed with flow cytometry. GNLY apoptotic protein was visualised by immunocytochemistry. Natural killer (NK) cell cytotoxicity was analysed with a cytotoxicity assay against human erythroleukaemia K-562 cells. The percentage of GNLY(+) cells did not differ significantly between PsA patients in the acute phase and those in remission; however, it was always higher than in healthy examinees due to the increased percentage of GNLY(+) cells within T cells, NKT cells, and both, and in the CD56(+dim) and CD56(+bright) NK subsets. The mean fluorescence intensity for GNLY was higher in all lymphocyte subpopulations in the acute phase than in remission and in healthy controls. Accordingly, GNLY-mediated NK cell cytotoxicity against K-562 cells of active phase PsA patients was significantly higher than that in patients in remission or in healthy controls. These findings demonstrated the involvement of GNLY in the worsening of PsA and suggested that GNLY mediated the development of joint lesions.
authors.affiliation: Thalassotherapia Opatija, Special Hospital for Rehabilitation of Hearth and Lung Diseases and Rheumatism, M. Tita 188, 51410 Opatija, Croatia.
authors.forename: Drazen
authors.initials: D
authors.lastname: Massari
authors.forename: Larisa
authors.initials: L
authors.lastname: Prpic-Massari
authors.forename: Tatjana
authors.initials: T
authors.lastname: Kehler
authors.forename: Marija
authors.initials: M
authors.lastname: Kastelan
authors.forename: Bozidar
authors.initials: B
authors.lastname: Curkovic
authors.forename: Viktor
authors.initials: V
authors.lastname: Persic
authors.forename: Alen
authors.initials: A
authors.lastname: Ruzic
authors.forename: Gordana
authors.initials: G
authors.lastname: Laskarin
mesh_terms: D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000502:physiology; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D017252:CD3 Complex / Q000378:metabolism; D019002:CD56 Antigen / Q000378:metabolism; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic / Q000502:physiology*; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology / Q000473:pathology*; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012074:Remission Induction; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000473:pathology*
chemical_list: D000945:Antigens, Differentiation, T-Lymphocyte; D018501:Antirheumatic Agents; D017252:CD3 Complex; D019002:CD56 Antigen; C075005:GNLY protein, human